Гараева З.Ш., Куклин В.Т., Зинкевич О.Д.

59
616.517'092'097
.
,
,
.
,
.
.
'
'
'
'
,
.
5'12
(
220
,
:
,
0,01
9,6)
.
'
18'
,
4°
1%'
,
,
.
.
40
'
'
'
,
.
(
7,2'7,4)
0,05%
37° .
,
'80
,
'
'
'
.
,
(
5,0).
.
120
.
.
,
'
'
'
G,
.
'
[5].
,
,
8
,
,
'
'
'
'
.
,
(
6'7
,
18
0,5'4
'
'
. 12
' E. coli –
18
'
32
18
5–
7–
.
20
.
'
,
'
.
5
'
'
'
'
P. aeruginosa –
'
,
10
. 1).
E. coli
.
.
'
'
.
,
65
'
'
'
,
4'5
.
.
.
,
'
,
30
.
'
P. aeruginosa.
1
'
'
(M±m)
'
,
(75%)
(25%).
'
'
Staphylococcus
aureus, Pseudomonas aeruginosa, Streptococcus pyogenes,
E. coli
P. aeruginosa
C. albicans
Bifidobacterium
1,32±0,161
3,54±0,611
1,98±0,661
22,40±5,321
1,04±0,131
1
Candida albicans, Klebsiella pneumoniae, Bacteroides S. aureus
S. piogenes
fragilis, Bifidobacterium spp., Escherihia coli
K. pneumoniae
Salmonella enteritidis ser. minnesota
1
(RE'595) [3].
80
'
2
3,47±0,99
29,80±6,502
9,70±1,951
1,42±0,231
3,78±0,601
1,98±0,301
27,99±7,40
1,29±0,181
3,00±0,511
8,36±0,39
15,60±0,59
14,48±0,61
25,08±0,76
4,27±0,29
6,55±0,22
29,60±7,402
12,90±3,311
13,75±0,55
25,25±0,86
.
.
60
,
,
,
.
,
'
.
'
–
.
'
'
.
.
,
C. albicans
,
,
,
.
'
S. pyogenes
'
[4],
'
.
,
,
S. pyogenes
.
,
'
'
'
'
,
,
'
'
'
, ,
,
[5].
,
.
(16
,
'
'
'
,
.
,
.
)
'
.
'
[2],
10'100
'
'
'
,
,
.
,
'
'
.
'
'
'
'
'
'
'
,
'
[6]
'
'
'
,
,
.
.
,
'
.
'
'
[1].
'
1.
.
2.
'
' 3.
,
[5].
'
4.
monia, B. fragilis
,
,
(13),
(
16
(
60
.,
.//
. – 2000. – 3. – . 41_45.
.,
.
,
.
.//
.
.
:
.
.–
, 2001. – . 50_51.
.
.//
,
_
. – 1999. –
2. – . 65_68.
.//
,
. – 1998. –
2. – . 9_12.
.,
.//
. – 1997. –
8. – . 4_7.
.,
.,
.
– .:
, 1989.
. 5.
S. aureus, Bifidobacterium spp., K. pneu_
,
' 6.
( 2'3
).
15.05.03.
,
' THE ROLE OF HUMORAL ANTIBACTERIAL IMMUNITY
.
' IN PATHOGENESIS OF PSORIASIS
Z.Sh. Garaeva, V.T. Kuklin, O.D. Zinkevich
C. albicans
' Epidemiology_and_Microbiology Scientific Research Institute
' of Khazan, Khazan State Medical Academy
(17)
' Summary – The authors studied humoral immunity state of 32
patients with psoriasis. On the ground of antibodies detection to
60
1
).
' gut organisms it is recommended to lower the humoral immune
response level under this disease notwithstanding the traditional
' therapy. The group of the scientists considers that there is a need
,
' to treat medically concomitant gastrointestinal tract diseases and
normalize microbiocenosis of bowels for effective host defenses
2
.
' recovery.
Pacific Medical Journal, 2003, No. 2, P. 59_60.
).